Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
RNAC 
Cartesian Therapeutics Inc. (RNAC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/04/2025: RNAC (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -33.33% | Avg. Invested days 23 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/04/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 259.07M USD | Price to earnings Ratio - | 1Y Target Price 37.33 |
Price to earnings Ratio - | 1Y Target Price 37.33 | ||
Volume (30-day avg) 103686 | Beta 0.83 | 52 Weeks Range 9.12 - 41.87 | Updated Date 04/5/2025 |
52 Weeks Range 9.12 - 41.87 | Updated Date 04/5/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.49 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -198.97% | Operating Margin (TTM) 2523.32% |
Management Effectiveness
Return on Assets (TTM) -6% | Return on Equity (TTM) -7029.26% |
Valuation
Trailing PE - | Forward PE 25.45 | Enterprise Value 59926867 | Price to Sales(TTM) 6.66 |
Enterprise Value 59926867 | Price to Sales(TTM) 6.66 | ||
Enterprise Value to Revenue 1.54 | Enterprise Value to EBITDA -1.17 | Shares Outstanding 25907100 | Shares Floating 9459460 |
Shares Outstanding 25907100 | Shares Floating 9459460 | ||
Percent Insiders 59.28 | Percent Institutions 26.66 |
Analyst Ratings
Rating 4.25 | Target Price 43 | Buy 2 | Strong Buy 4 |
Buy 2 | Strong Buy 4 | ||
Hold 2 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Cartesian Therapeutics Inc.
Company Overview
History and Background
Cartesian Therapeutics, Inc. is a clinical-stage biotechnology company pioneering RNA cell therapy for autoimmune diseases. Founded in 2016, the company focuses on developing engineered cell therapies that address the underlying causes of these diseases. The company has transitioned from preclinical research to clinical trials.
Core Business Areas
- RNA Cell Therapy: Developing and commercializing RNA cell therapies targeting autoimmune diseases.
- Descartes-DNA platform: Using its proprietary Descartes-DNA platform to design and manufacture RNA cell therapies. The Descartes-DNA platform is a cell engineering platform where cells are engineered ex vivo using mRNA.
Leadership and Structure
Dr. Murat V. Kalayoglu is the President and CEO. The company has a board of directors and a management team focused on research, development, and clinical operations.
Top Products and Market Share
Key Offerings
- Descartes-08: An RNA-engineered CAR-T cell therapy in clinical development for the treatment of generalized myasthenia gravis (gMG). There is no market share data available as it is still in development. Competitors include companies developing other CAR-T therapies, as well as those offering existing treatments such as acetylcholinesterase inhibitors and immunotherapies.
- Descartes-30: An RNA-engineered CAR-T cell therapy in clinical development for the treatment of relapsed or refractory multiple myeloma (RRMM). There is no market share data available as it is still in development. Competitors include companies developing other CAR-T therapies, as well as those offering existing treatments such as proteasome inhibitors, immunomodulatory drugs, and chemotherapy.
Market Dynamics
Industry Overview
The biotechnology industry, particularly the cell and gene therapy sector, is experiencing rapid growth driven by technological advancements and increasing investment. The autoimmune disease market is a large and growing segment with significant unmet medical needs.
Positioning
Cartesian Therapeutics is positioned as an innovator in RNA cell therapy for autoimmune diseases. Its competitive advantage lies in its Descartes-DNA platform, which enables precise and controlled engineering of cells.
Total Addressable Market (TAM)
The total addressable market for autoimmune disease therapies is estimated to be in the tens of billions of dollars annually. Cartesian is positioned to capture a portion of this market by offering potentially curative therapies for specific autoimmune conditions.
Upturn SWOT Analysis
Strengths
- Proprietary Descartes-DNA platform
- Focus on RNA cell therapy
- Strong leadership team
- Clinical-stage assets
Weaknesses
- Limited revenue stream (clinical stage)
- High research and development costs
- Reliance on successful clinical trial outcomes
- Relatively small company size
Opportunities
- Successful clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion into new autoimmune indications
- Advancements in cell therapy technology
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established pharmaceutical companies
- Patent disputes
Competitors and Market Share
Key Competitors
- BLUE
- CRSP
- EDIT
Competitive Landscape
Cartesian differentiates itself with its Descartes-DNA platform for RNA cell therapy, targeting a specific approach to treat autoimmune diseases and cancers. Major competitors have diverse portfolios of gene editing and cell therapy technologies.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by preclinical and early clinical development activities.
Future Projections: Future growth depends on successful completion of clinical trials and regulatory approvals. Analyst estimates depend on specific clinical data, with potential for significant revenue upon commercialization.
Recent Initiatives: Recent initiatives include advancing clinical trials for Descartes-08 and Descartes-30, presenting clinical data at scientific conferences, and securing funding.
Summary
Cartesian Therapeutics is a clinical-stage biotech company focused on RNA cell therapy for autoimmune diseases, possessing a novel technology platform and addressing substantial unmet medical needs. Its success hinges on favorable clinical trial results, adept navigation of the regulatory landscape, and its ability to carve out a significant share in a highly competitive market. Given it's a clinical-stage company, investors should monitor developments closely. The company is high risk and high reward.
Similar Companies
BLUE
Bluebird bio Inc
BLUE
Bluebird bio Inc
CRSP
Crispr Therapeutics AG
CRSP
Crispr Therapeutics AG
EDIT
Editas Medicine Inc
EDIT
Editas Medicine Inc
GILD
Gilead Sciences Inc
GILD
Gilead Sciences Inc
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Financial data and market information are subject to change. Invest at your own risk.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cartesian Therapeutics Inc.
Exchange NASDAQ | Headquaters Frederick, MD, United States | ||
IPO Launch date 2016-06-22 | President, CEO & Director Dr. Carsten Brunn Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 66 | |
Full time employees 66 | |||
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA CAR-T directed against the B cell maturation antigen (BCMA) for the treatment of autoimmune diseases, currently under Phase 2b clinical development for generalized myasthenia gravis, systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It develops Descartes-15, an autologous anti-BCMA mRNA CAR-T to treat autoimmune diseases such as relapsed/refractory multiple myeloma. Cartesian Therapeutics, Inc. is headquartered in Frederick, Maryland.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.